[1] |
Linder KA, Malani PN. Meningococcal meningitis[J]. JAMA, 2019, 321(10): 1014. doi: 10.1001/jama.2019.0772
|
[2] |
杨俊峰, 李艺星, 尹遵栋, 等. 2004 — 2005年我国流行性脑脊髓膜炎病死率分析[J]. 中国公共卫生, 2006, 22(12): 1518 – 1519. doi: 10.11847/zgggws2006-22-12-65
|
[3] |
Olbrich KJ, Müller D, Schumacher S, et al. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers[J]. Infectious Diseases and Therapy, 2018, 7(4): 421 – 438. doi: 10.1007/s40121-018-0213-2
|
[4] |
Xu YH, Li YN, Wang SS, et al. Meningococcal vaccines in China[J]. Human Vaccines and Immunotherapeutics, 2021, 17(7): 2197 – 2204. doi: 10.1080/21645515.2020.1857201
|
[5] |
国家卫生健康委. 2019年全国法定传染病疫情概况[R]. 北京: 国家卫生健康委, 2002.
|
[6] |
国家卫生健康委. 2020年全国法定传染疫情概况[R]. 北京: 国家卫生健康委, 2021.
|
[7] |
Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the poten-tial for prevention through vaccination[J]. Journal of Infection, 2020, 81(4): 483 – 498. doi: 10.1016/j.jinf.2020.05.079
|
[8] |
Pan JR, Yao PP, Zhang H, et al. The case of a new sequence type 7 serogroup X Neisseria meningitidis infection in China: may capsular switching change serogroup profile?[J]. International Journal of Infectious Diseases, 2014, 29: 62 – 64. doi: 10.1016/j.ijid.2014.07.022
|
[9] |
邵祝军, 徐丽, 高源, 等. 中国流行性脑脊髓膜炎流行菌群变化趋势分析[J]. 中国计划免疫, 2007, 13(6): 541 – 544. doi: 10.3969/j.issn.1006-916X.2007.06.008
|
[10] |
Shao ZJ, Li W, Ren J, et al. Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China[J]. The Lancet, 2006, 367: 419 – 423. doi: 10.1016/S0140-6736(06)68141-5
|
[11] |
李军宏, 吴丹, 温宁, 等. 2015 — 2019年中国流行性脑脊髓膜炎血清群分布特征[J]. 中国疫苗和免疫, 2020, 26(3): 241 – 244.
|
[12] |
赵盼, 朱兵清, 张艾煜, 等. 中国脑膜炎奈瑟菌ST-4821克隆群荚膜基因簇分布特征[J]. 疾病监测, 2020, 35(6): 508 – 512. doi: 10.3784/j.issn.1003-9961.2020.06.011
|
[13] |
国家卫生健康委. 国家卫生健康委关于印发国家免疫规划疫苗儿童免疫程序及说明 (2021年版) 的通知[EB/OL]. (2021 – 03 – 12)[2021 – 08 – 10]. http://www.nhc.gov.cn/jkj/s3581/202103/590a8c7915054aa682a8d2ae8199e222.shtml.
|
[14] |
柴志凯, 李军, 邵祝军, 等. 流行性脑脊髓膜炎监测与免疫预防专家研讨会会议纪要[J]. 中国预防医学杂志, 2015, 16(12): 901 – 903.
|
[15] |
Weintraub A. Immunology of bacterial polysaccharide antigens[J]. Carbohydrate Research, 2003, 338(23): 2539 – 2547. doi: 10.1016/j.carres.2003.07.008
|
[16] |
赵东阳, 谢志强, 苟锦博, 等. 3月龄婴儿接种A群C群脑膜炎球菌多糖结合疫苗的免疫原性和不良反应[J]. 中国疫苗和免疫, 2020, 26(4): 387 – 390.
|
[17] |
国家药品监督管理局. 国产药品数据查询[DB/OL]. 北京: 国家药品监督管理局, (2021 – 08 – 08) [2020 – 08 – 11]. http://app1.nmpa.gov.cn/data_nmpa/face3/base.jsp?tableId=25&tableName=TABLE25&title=%B9%FA%B2%FA%D2%A9%C6%B7&bcId=152904713761213296322795806604&CbSlDlH0=qGk8qacgXhPgXhPgXJnJaEDBV6WPKdJ3CcEJcwU4a_3qqhG.
|
[18] |
Kurosky SK, Davis KL, Krishnarajah G. Effect of combination vaccines on completion and compliance of childhood vaccinations in the United States[J]. Human Vaccines and Immunotherapeutics, 2017, 13(11): 2494 – 2502. doi: 10.1080/21645515.2017.1362515
|
[19] |
Klein NP, Abu-Elyazeed R, Baine Y, et al. Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants[J]. Human Vaccines and Immunotherapeutics, 2019, 15(2): 327 – 338. doi: 10.1080/21645515.2018.1526586
|
[20] |
李亚南, 梁丽, 李艳萍, 等. A、C群脑膜炎球菌 – b型流感嗜血杆菌多糖结合疫苗免疫学效果观察[J]. 中国生物制品学杂志, 2012, 25(9): 1190 – 1194,1197.
|
[21] |
李江嵘, 杨军, 刘晓强, 等. AC群脑膜炎球菌 (结合) b型流感嗜血杆菌 (结合) 联合疫苗上市后2~71月龄儿童接种的安全性研究[J]. 中国疫苗和免疫, 2016, 22(5): 578 – 581.
|
[22] |
Li YX, Yin ZD, Shao ZJ, et al. Population-based surveillance for bacterial meningitis in China, September 2006 – December 2009[J]. Emerging Infectious Diseases, 2014, 20(1): 61 – 69.
|
[23] |
吴丹, 李艺星, 邵祝军, 等. 2006 — 2013年中国4个城市急性脑膜炎脑炎流行病学疾病负担研究[J]. 中华预防医学杂志, 2019, 53(2): 164 – 168.
|
[24] |
邵祝军. 流行性脑脊髓膜炎流行现状及防控形势[J]. 中华预防医学杂志, 2019, 53(2): 129 – 132.
|
[25] |
中华预防医学会. 脑膜炎球菌疫苗的有效性、安全性和成本效益研究进展[J]. 中华流行病学杂志, 2019, 40(2): 129 – 135. doi: 10.3760/cma.j.issn.0254-6450.2019.02.002
|
[26] |
李军宏, 李艺星, 吴丹, 等. 中国2006 — 2014年流行性脑脊髓膜炎病例菌群分布特征及变迁趋势[J]. 中国疫苗和免疫, 2015, 21(5): 481 – 485.
|
[27] |
吴疆. 中国脑膜炎球菌疫苗预防接种专家共识[J]. 中华预防医学杂志, 2019, 53(2): 141 – 145.
|
[28] |
Parikh SR, Newbold L, Slater S, et al. Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment[J]. The Lancet Infectious Diseases, 2017, 17(7): 754 – 762. doi: 10.1016/S1473-3099(17)30170-6
|
[29] |
Ostergaard L, Lucksinger GH, Absalon J, et al. A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults[J]. Vaccine, 2016, 34(12): 1465 – 1471. doi: 10.1016/j.vaccine.2016.01.044
|
[30] |
朱兵清, 高婉迎, 徐丽, 等. 中国B群脑膜炎奈瑟菌分子流行病学特征分析[J]. 中华预防医学杂志, 2019, 53(2): 153 – 158.
|